Lilly's $2.25B bet - Biotech AI Model Stack Structural Shift Lilly- Profluent AI-designed gene editor, OpenAI's GPT-Rosalind with Amgen, Novo, Moderna and BMS' 30,000 Claude Agents

This week's pharma AI operating system is in focus, where we discuss Billions in M&A, Investments with AI in Biotech, with Credible pivotal regulatory intelligence read through. Eli Lilly signed a $2.25B pact with Profluent for AI-designed gene editorsBristol Myers Squibb deployed Anthropic's Claude across 30,000 employees, and OpenAI launched GPT-Rosalind with Novo Nordisk, Moderna, and Amgen as first partners. Behind those headlines is a structural shift: pharma is no longer experimenting with AI — it is choosing among three foundation-model stacks (OpenAI, Anthropic, DeepMind/Isomorphic) that will define the next decade of R&D, regulatory, and manufacturing. In chapter beats, we talk about: (1) The Three-Stack Era of Foundational Models (2) Lilly × Profluent. (3) BMS × Anthropic. (4) GPT-Rosalind. (5) M&A at $106B YTD. (6) ASCO readouts, ADCs, in-vivo CAR-T. (7) Regulatory read-through. (8) Strategic foresight.